Literature DB >> 33300973

Change in Postoperative Opioid Prescribing Patterns for Oculoplastic and Orbital Procedures Associated With State Opioid Legislation.

Yanjun Xie1, Andrew W Joseph1, Shannon F Rudy1, Victor M Elner2, Hakan Demirci2, Denise S Kim2, Christine C Nelson2, Shannon S Joseph2.   

Abstract

Importance: Understanding whether statewide legislation, such as the Michigan Opioid Laws, is associated with reduction in postoperative opioid prescriptions is informative in guiding future legislation. Objective: To identify changes in opioid prescribing patterns for oculoplastic and orbital procedures associated with the enactment of the Michigan Opioid Laws in 2017 and 2018. Design, Setting, and Participants: This cross-sectional study included 3781 patients who underwent any of 10 common oculoplastic and orbital procedures between June 1, 2016, and November 30, 2019, at a tertiary care institution. Exposures: From 2017 to 2018, Michigan enacted a series of laws to address the state's worsening opioid epidemic. Two major components of this legislation enacted on June 1, 2018, required prescribers to review a report of patients' opioid use history and obtain signed consent after educating patients on the use and disposal of opioids prior to prescribing. Main Outcomes and Measures: Demographic information, type of surgery, type and amount of opioid prescriptions, and morphine milligram equivalent (MME) were analyzed. MME was calculated as the product of dose, quantity, and opioid-specific conversion factor for each prescription. Linear interpolation spline regression was used to evaluate the association of prescription MME with time.
Results: Of 3781 patients, 1614 (42.7%) were male. The mean (SD) age at the time of surgery was 63.3 (16.6) years. Of 2026 patients undergoing surgery before June 1, 2018, 1782 (88.0%) were prescribed postoperative opioids; of 1755 patients undergoing surgery after June 1, 2018, 878 (50.0%) were prescribed postoperative opioids (P < .001). There was no difference in age, sex, race/ethnicity, surgery type, or opioids prescribed between these 2 cohorts. Linear interpolation spline regression showed a decrease of 26.025 MMEs (equivalent to a 36.2% reduction of mean MME) between June 1, 2017, and September 30, 2018 (β, -1.735; 95% CI, -0.088 to -0.024; P < .001), stabilizing at a persistently reduced rate of MME prescribed through the end of the study period (October 1, 2018, to November 30, 2019; β, -0.005; 95% CI, -0.039 to 0.016; P = .42). Changes in MME in the 12 months before or 12 months after the period of legislation enactment were not identified. Conclusions and Relevance: In this cross-sectional study, reduction in opioid prescriptions for oculoplastic and orbital procedures was observed during the enactment period of the Michigan Opioid Laws and appeared to be sustained through the end of the study period. Similar statewide or national legislations aimed at increasing prescriber awareness and patient education on opioid use may help curtail the prescription opioid epidemic.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33300973      PMCID: PMC7729578          DOI: 10.1001/jamaophthalmol.2020.5446

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  4 in total

1.  Error in Data Presentation in Text.

Authors: 
Journal:  JAMA Ophthalmol       Date:  2021-02-01       Impact factor: 7.389

2.  Opioid Prescribing Patterns for Ulcerative Keratitis.

Authors:  Alexa R Thibodeau; Leslie M Niziol; Bradford L Tannen; Dena Ballouz; Maria A Woodward
Journal:  Cornea       Date:  2022-04-01       Impact factor: 2.651

3.  Opioid prescribing patterns among oculofacial plastic surgeons.

Authors:  Amisha D Dave; Madina Falcone
Journal:  Int Ophthalmol       Date:  2022-07-22       Impact factor: 2.029

4.  Persistent Opioid Use after Ophthalmic Surgery in Opioid-Naive Patients and Associated Risk Factors.

Authors:  Cindy Ung; Yoshihiro Yonekawa; Jennifer F Waljee; Vidhya Gunaseelan; Yen-Ling Lai; Maria A Woodward
Journal:  Ophthalmology       Date:  2021-04-22       Impact factor: 14.277

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.